Navigation Links
OxThera Strengthens Patent Portfolio for Orphan Disease - Primary Hyperoxaluria
Date:6/4/2013

STOCKHOLM, June 4, 2013 /PRNewswire/ --

OxThera AB has been granted three Japanese patents during 2012 and 2013. The patents will secure the pharmaceutical composition and the method for treating and preventing oxalate-related disease with micro-organisms and enzymes and will further strengthen the Company's patent estate for this unmet medical need.

"We are continuously working to further strengthen the world-wide rights for our lead product Oxabact®" for treatment of Primary Hyperoxaluria, an orphan disease," says Elisabeth Lindner , CEO of OxThera. "The Japanese rights are important additions to our already granted patents in the EU and the US. Japan is an important market for hyperoxaluria" Elisabeth Lindner continues.

OxThera holds proprietary rights to pharmaceutical preparations and their use for treatment of hyperoxaluria in seven patent families with approximately eighty applications filed. The new granted Japanese patents have numbers 4996780, 5047190 and 5203217.

Oxabact® is an oral product composed of highly concentrated freeze-dried live bacteria (Oxalobacter formigenes), administered in capsules. The drug is designed for delivery in the lower part of the small intestine, where enteric elimination of endogenous oxalate is initiated. OxThera is currently pursuing a complete Oxabact® clinical development plan in the EU and in the US for the treatment of patients suffering from Primary Hyperoxaluria.

About Primary Hyperoxaluria

Primary Hyperoxaluria is a rare inborn autosomal genetic disorder leading to markedly elevated levels of endogenous oxalate in plasma and urine. High levels of urinary oxalate cause kidney damage, including kidney stone formation and/or calcification of the kidney. If left untreated, the disease can cause kidney failure and premature death. There is a high medical need for effective treatments of Primary Hyperoxaluria. Currently, the only available cure is a combined liver and kidney transplantation.

Oxabact® holds orphan drug designations in the EU and the US for the treatment of Primary Hyperoxaluria.

About OxThera

OxThera holds worldwide rights for compositions and methods of use for treatment of hyperoxaluria. OxThera currently has two products in its pipeline: Oxabact® for the treatment of Primary Hyperoxaluria, and Oxazyme®, an oxalate decarboxylase, for the prevention of oxalate malabsorption and recurring kidney stones in Secondary Hyperoxaluria. OxThera operates through the head office in Stockholm, Sweden, and its subsidiary OxThera Inc. in Alachua, Florida, USA.

For further information, please contact Elisabeth Lindner , CEO of OxThera AB, Phone +46-8-660-02-23


http://www.oxthera.com


'/>"/>
SOURCE OxThera
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CareFusion Strengthens U.K. Presence With Acquisition of Medical Products Distributor
2. Tris Pharma Expands Manufacturing Capacity and Strengthens Supply Chain to Support New and Pending Approvals
3. RxAlly Strengthens Leadership Team With New Chief Information Officer Mike Groh
4. PAREXEL Strengthens Outcomes Research Capabilities To Help Biopharma Meet Commercialization Goals
5. Actinium Pharmaceuticals Strengthens Management Team
6. Pharmalink AB Strengthens Senior Management Team
7. Jardogs Strengthens Leadership Team with the Addition of Two Seasoned Healthcare Executives
8. inVentiv Health Strengthens Clinical Leadership Team
9. Alliqua Strengthens and Realigns Executive Team
10. Neuland Labs Strengthens Commitment to Japanese Market With New Manufacturing Collaboration With Mitsubishi Healthcare Unit API Corporation
11. TransCelerate BioPharma Inc. Grows, Strengthens Novel Effort to Accelerate Drug Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2017)... Datascope Corp. is voluntarily performing a worldwide field correction of ... test failure code.     ... PART NUMBER ... 0998-UC-0446HXX; 0998-UC-0479HXX 0998-00-3013-XX;  0998-UC-3013-XX ... This field correction also applies to ...
(Date:6/14/2017)... June 14, 2017  In 2016, Embodied Labs ... pitch competition and came away with $25,000 in ... described by Forbes as "entering the life of another" ... as teaching "empathy to medical professionals in an entirely ... recently named a finalist for the Department of Education,s ...
(Date:6/10/2017)... 2017  Shane K. Burchfield, DPM, is recognized by Continental Who,s ... Podiatrist in Alabama . Dr. ... Care. He brings over 20 years of experience, as well as ... to his role. ... pleased to welcome you to his practice," the company,s ...
Breaking Medicine Technology:
(Date:6/25/2017)... ... 2017 , ... An increase in wetter weather in the Northern California area ... that; a humdinger of an allergy season. A relief from drought conditions is most ... grass and weed pollen. , “Our patients have been reporting the typical allergy ...
(Date:6/25/2017)... ... ... a heatwave currently bearing down on Northern California pushing temperatures to the maximum, many people ... easy with laser hair removal. , The process of summer waxing and constantly shaving ... you want to do is get out, dive in and cool off. There is a ...
(Date:6/24/2017)... ... June 24, 2017 , ... Genes Advice, ... medications in select Florida and Texas doctors' offices and clinics. This breakthrough testing ... of genetic testing recognizes the role genes play in determining an individual's tolerance ...
(Date:6/24/2017)... (PRWEB) , ... June 24, 2017 , ... ... Dental365 family. Located at 217 Portion Road in Lake Ronkonkoma, Dental365 offers patients ... and weekends so that visits to the dentist fit into their patients’ busy ...
(Date:6/24/2017)... ... June 24, 2017 , ... Doorknobs are for convenience, deadbolts are for ... a guard dog or having an alarm system installed. But unless there is a ... Yair Frenkel, owner of TX Premier Locksmith in Killeen, TX says: “In the majority ...
Breaking Medicine News(10 mins):